vs
Side-by-side financial comparison of Brookfield Renewable Partners L.P. (BEP) and Bausch Health Companies Inc. (BHC). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $1.7B, roughly 1.7× Brookfield Renewable Partners L.P.). Brookfield Renewable Partners L.P. runs the higher net margin — 5.9% vs -3.7%, a 9.6% gap on every dollar of revenue. On growth, Brookfield Renewable Partners L.P. posted the faster year-over-year revenue change (14.2% vs 9.3%).
Brookfield Renewable Partners L.P.BEPEarnings & Financial Report
Brookfield Renewable Partners L.P. is a publicly traded limited partnership that owns and operates renewable power assets, with corporate headquarters in Toronto, Ontario, Canada. It is 60% owned by Brookfield Asset Management.
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
BEP vs BHC — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.7B | $2.8B |
| Net Profit | $100.0M | $-103.0M |
| Gross Margin | — | — |
| Operating Margin | — | 17.0% |
| Net Margin | 5.9% | -3.7% |
| Revenue YoY | 14.2% | 9.3% |
| Net Profit YoY | 213.6% | -205.1% |
| EPS (diluted) | $-0.22 | $-0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.8B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | $1.7B | $2.5B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | $1.5B | $2.4B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | — | $-103.0M | ||
| Q3 25 | — | $179.0M | ||
| Q2 25 | $100.0M | $148.0M | ||
| Q1 25 | — | $-58.0M | ||
| Q4 24 | — | $98.0M | ||
| Q3 24 | — | $-85.0M | ||
| Q2 24 | $-88.0M | $10.0M | ||
| Q1 24 | — | $-64.0M |
| Q4 25 | — | 17.0% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 17.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 21.8% | ||
| Q3 24 | — | 12.7% | ||
| Q2 24 | — | 16.2% | ||
| Q1 24 | — | 13.1% |
| Q4 25 | — | -3.7% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | 5.9% | 5.8% | ||
| Q1 25 | — | -2.6% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | -3.4% | ||
| Q2 24 | -5.9% | 0.4% | ||
| Q1 24 | — | -3.0% |
| Q4 25 | — | $-0.30 | ||
| Q3 25 | — | $0.48 | ||
| Q2 25 | $-0.22 | $0.40 | ||
| Q1 25 | — | $-0.16 | ||
| Q4 24 | — | $0.24 | ||
| Q3 24 | — | $-0.23 | ||
| Q2 24 | $-0.28 | $0.03 | ||
| Q1 24 | — | $-0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9B | $1.3B |
| Total DebtLower is stronger | — | $20.8B |
| Stockholders' EquityBook value | $33.3B | $-554.0M |
| Total Assets | $98.6B | $26.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $1.9B | $1.7B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $719.0M | ||
| Q2 24 | $1.2B | $595.0M | ||
| Q1 24 | — | $733.0M |
| Q4 25 | — | $20.8B | ||
| Q3 25 | — | $21.0B | ||
| Q2 25 | — | $21.7B | ||
| Q1 25 | — | $21.5B | ||
| Q4 24 | — | $21.6B | ||
| Q3 24 | — | $21.5B | ||
| Q2 24 | — | $21.7B | ||
| Q1 24 | — | $22.1B |
| Q4 25 | — | $-554.0M | ||
| Q3 25 | — | $-565.0M | ||
| Q2 25 | $33.3B | $-764.0M | ||
| Q1 25 | — | $-1.2B | ||
| Q4 24 | — | $-1.3B | ||
| Q3 24 | — | $-1.2B | ||
| Q2 24 | $28.0B | $-1.2B | ||
| Q1 24 | — | $-1.1B |
| Q4 25 | — | $26.4B | ||
| Q3 25 | — | $26.8B | ||
| Q2 25 | $98.6B | $27.3B | ||
| Q1 25 | — | $26.4B | ||
| Q4 24 | — | $26.5B | ||
| Q3 24 | — | $26.5B | ||
| Q2 24 | $73.8B | $26.5B | ||
| Q1 24 | — | $26.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $379.0M | $495.0M |
| Free Cash FlowOCF − Capex | — | $403.0M |
| FCF MarginFCF / Revenue | — | 14.4% |
| Capex IntensityCapex / Revenue | — | 3.3% |
| Cash ConversionOCF / Net Profit | 3.79× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $495.0M | ||
| Q3 25 | — | $405.0M | ||
| Q2 25 | $379.0M | $289.0M | ||
| Q1 25 | — | $211.0M | ||
| Q4 24 | — | $601.0M | ||
| Q3 24 | — | $405.0M | ||
| Q2 24 | $231.0M | $380.0M | ||
| Q1 24 | — | $211.0M |
| Q4 25 | — | $403.0M | ||
| Q3 25 | — | $314.0M | ||
| Q2 25 | — | $190.0M | ||
| Q1 25 | — | $96.0M | ||
| Q4 24 | — | $495.0M | ||
| Q3 24 | — | $334.0M | ||
| Q2 24 | — | $302.0M | ||
| Q1 24 | — | $129.0M |
| Q4 25 | — | 14.4% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | — | 13.3% | ||
| Q2 24 | — | 12.6% | ||
| Q1 24 | — | 6.0% |
| Q4 25 | — | 3.3% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | — | 2.8% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 3.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.26× | ||
| Q2 25 | 3.79× | 1.95× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 6.13× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 38.00× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BEP
Segment breakdown not available.
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
